EMI56

Cat. No.: HY-131067

CAS No.: 2414374-41-5

Molecular Formula: $C_{21}H_{20}N_2O_3$

Molecular Weight: 348.4

Target: EGFR

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (143.51 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.8703 mL	14.3513 mL	28.7026 mL
	5 mM	0.5741 mL	2.8703 mL	5.7405 mL
	10 mM	0.2870 mL	1.4351 mL	2.8703 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.08 mg/mL (5.97 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants[1].

IC_{50} & Target

$EGFR^{L858R/T790M/C797S}$	$EGFR^{del19\ T790M\ C797S}$

In Vitro

EMI56 inhibits EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. EMI56 can be used in the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC)[1].

EMI56 (10, 15, 20 μM; 2 h of treatment) strongly inhibits total EGFR levels, activation and downstream signaling in PC9 EGFR ex19del/T790M/C797S cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	PC9 EGFR ex19del/T790M/C797S cells
Concentration:	1, 5, 10, 15, 20 μM
Incubation Time:	2 hours
Result:	Inhibited total EGFR levels from 10 μM concentration.

REFERENCES

[1]. Punit Saraon, et al. A Drug Discovery Platform to Identify Compounds That Inhibit EGFR Triple Mutants.Nat Chem Biol. 2020 May;16(5):577-586.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA